Category: October 2025

  • FDA Generic Drug Review Boosts US Drug Manufacturing

    The US Food and Drug Administration (FDA) has announced the launch of a new pilot programme. This programme aims to accelerate the review process for generic drugs. Companies research, develop, and manufacture these drugs entirely within the United States. The initiative aims to incentivise pharmaceutical companies to onshore their operations. It strengthens the domestic supply chain and reduces America’s heavy…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • African Health Financing Must be Forged in Africa

    South Africa’s Finance Minister, Enoch Godongwana, has warned that Africa must urgently develop self-reliant funding mechanisms for its healthcare sector. This includes implementing taxes on products such as tobacco and alcohol. The continent faces a significant and “distressing decline” in foreign aid. His call highlights the critical need to strengthen African health financing and ensure the sustainability of healthcare systems.…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Medical Device Regulation and Its Importance Today

    Millions of medical devices are used daily in South Africa. These range from simple bandages to complex pacemakers. Patients often assume these products are tested and safe. However, a significant regulatory gap exists. This oversight can pose a substantial risk to public health. The urgent need for comprehensive medical device regulation is clear. Faulty devices create dangerous situations. For example,…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Pfizer Drug Pricing Deal Sees Stocks Soar

    In a move heralded by President Donald Trump as a monumental victory for American consumers, pharmaceutical giant Pfizer has agreed to a deal that promises to slash the prices of some of its drugs. However, the market’s reaction has told a very different story. This reaction raises questions about the actual impact of the agreement on the firm’s bottom line…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in